Filgrastim

It is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes.

Indications

Cancer patients receiving Myelosuppressive Chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, Patients udergoing peripheral blood progenitor cell collection and therapy, to treat neutropenia caused due to chemotherapy or bone marrow transplantation.

Dosage

5 mcg/kg or 200mcg/m2 for up to 2 weeks

Contra-Indications

Filgrastim shoud not be used in patients with known hypersensitivity to E.coli derived proteins.

Special Precautions

Pregnancy category C medication, used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Filgrastim can make sickle cell anamia worse, may stimulate the growth of cancer cells.

Side Effects

Mild-to-moderate bone pain after repeated administration and local skin reactions at the site of injection. Other adverse effects include splenic rupture, alveolar hemorrhage, acute respiratory distress syndrome (ARDS), and hemoptysis.

Drug Interactions

Lithium along with filgrastim can lead to overproduction of W.B.Cs which can lead to conditions like strokes and heart attacks. Filgrastim should be taken within 24 hours before or after chemotherapy.